Biogen stock climbs on strong Alzheimer’s drug sales
Much of the attention in the earnings report focused on Leqembi, which was developed by Biogen and its Japanese business partner, Eisai. It is the first drug that experts agree modestly slows the progression of Alzheimer’s disease in people with mild …